Evotec AG has entered into a research collaboration with The Leukemia & Lymphoma Society (LLS) to support one of LLS’s Screen-to-Lead Programs (SLP). Evotec will support selected programs and principal investigators with resources for high-throughput screening and optimization of small molecules into drug-like compounds. Financial details were not disclosed.   Dr. Mario Polywka, chief operating officer of Evotec, said, “We are excited to initiate this collaboration and support Th...